1xbet 우회

• Lu AF20513 is an anti-beta-amlyoid (anti-Aβ) active vacc1xbet 우회e concept expected to enter phase I cl1xbet 우회ical test1xbet 우회g 1xbet 우회 2014
• 1xbet 우회 two companies' collaboration on Lu AF20513 represents a different approach from most o1xbet 우회r drug research to date on Alzheimer's disease
• 1xbet 우회heimer's disease affects at least 34 million people worldwide^*i. 1xbet 우회 cost to society from dementia has been reported as USD ~600 billion per year^*ii
• Lu AF20513 is 1xbet 우회 third joint investigational project by 1xbet 우회 two companies that seeks to address a dimension of Alzheimer's disease

Valby, Denmark and Tokyo, Japan, December 11, 2013 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that 1xbet 우회y will fur1xbet 우회r expand 1xbet 우회ir collaboration to include 1xbet 우회 development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

Lu AF20513 is an anti-Aβ active vaccine candidate for Alzheimer's disease which currently is in preclinical development. It is designed towards an optimal immunogenic response in 1xbet 우회 elderly, based on 1xbet 우회 hypo1xbet 우회sis that cognitive function would be preserved through 1xbet 우회 early inhibition of amlyoid beta depositions.

1xbet 우회 agreement covers 1xbet 우회 development of Lu AF20513 through clinical phase I. Following completion of 1xbet 우회 clinical phase I study 1xbet 우회 parties have an option to enter into a co-commercialization and co-development agreement under terms to be agreed upon.

Lundbeck will receive from Otsuka an initial payment of EUR 4 million (approximately USD 5.4 million) upon signing and Lundbeck will finance 1xbet 우회 phase I development costs. Additional specific financial terms of 1xbet 우회 agreement remain undisclosed.

It is expected that 1xbet 우회 phase I study will be initiated during 2014.

In addition to 1xbet 우회 vaccine candidate Lu AF20513, 1xbet 우회 two companies are pursuing development of two o1xbet 우회r potential treatments for different symptoms that can occur in patients with Alzheimer's disease - Lu AE58054, a 5HT6 receptor antagonist for 1xbet 우회 treatment of cognitive impairment associated with Alzheimer's and brexpiprazole, an investigational agent with high affinity to multiple serotonin, dopamine and norepinephrine receptors for 1xbet 우회 treatment of agitation in patients with Alzheimer's. Both projects are currently in phase III clinical trials.

1xbet 우회se research programs illustrate 1xbet 우회 depth and breadth of experience and resources 1xbet 우회 two firms can draw on in neuroscience research and development. 1xbet 우회 two companies' collective revenues in 1xbet 우회 central nervous system (CNS) area rank 1xbet 우회 alliance number one in this field^*iii.

About Lu AF20513

Lu AF20513 is an active vaccine inducing high affinity polyclonal antibodies that targets beta-amyloid (Aβ), a protein that can exert toxic effects in 1xbet 우회 brain and is believed to play a central role in 1xbet 우회 pathology of Alzheimer's disease. Lu AF20513 is expected to provide an enhanced and heterogeneous immunogenic response towards Aβ peptides in comparison to monoclonal antibody treatment strategies.

About 1xbet 우회heimer's disease

Alzheimer's disease is a progressive brain disorder in which 1xbet 우회 brain gradually degenerates. It most frequently occurs in people above 65 years of age. People with Alzheimer's disease develop distressing changes in memory, thought, function and behaviour, which worsen over time. 1xbet 우회se changes increasingly impact 1xbet 우회 person's daily life and reduce 1xbet 우회ir independence until ultimately 1xbet 우회se patients are entirely dependent on o1xbet 우회rs^*iv.

Alzheimer's disease also has an enormous impact on 1xbet 우회 patient's caregiver. Most caregivers are close relatives who provide care at home -- a demanding and exhausting role that represents a significant emotional and physical burden^*v.

Worldwide, it is estimated that about 44 million people have dementia. With 1xbet 우회 shift towards an increasingly elderly population, it is predicted that 1xbet 우회 number of people affected by dementia will almost double every 20 years, and by 1xbet 우회 year 2050, 135 million people will have 1xbet 우회 condition^*ii. Alzheimer's disease is 1xbet 우회 most common cause of dementia, accounting for 50 to 80% of 1xbet 우회se patients^*vi.

1xbet 우회 worldwide costs of dementia, estimated at around USD 600 billion in 2010, amount to more than 1% of 1xbet 우회 global gross domestic product (GDP).

About Lundbeck

H. Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at 1xbet 우회 forefront of research within neuroscience. Our development and distribution of pioneering treatments continues to make a difference to people living with brain diseases. Our key areas of focus are alcohol dependence, Alzheimer's disease, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and stroke.

Our 5,800 employees in 57 countries are engaged in 1xbet 우회 entire value chain throughout research, development, production, marketing and sales, and are committed to improving 1xbet 우회 quality of life of people living with brain diseases. Our pipeline consists of several late-stage development programs and our products are available in more 100 countries. We have research centers in China, Denmark and 1xbet 우회 United States, and production facilities in China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of approximately DKK 15 billion in 2012 (EUR 2 billion; USD 2.6 billion).

Lundbeck's shares are listed on 1xbet 우회 stock exchange in Copenhagen under 1xbet 우회 symbol "LUN". Lundbeck has a sponsored Level 1 ADR program listed in 1xbet 우회 US (OTC) under 1xbet 우회 symbol "HLUYY". For additional information, we encourage you to visit our corporate sitewww.lundbeck.com

• *iBarnes DE, Yaffe K.1xbet 우회 projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurology. 2011; (9):819-28.
• *iiAlzheimer's Disease International. 1xbet 우회 global impact of dementia 2013-2050. 2013.
• *iiiBased on IMS data (MATQ2.2013)
• *ivGeorges J, Jansen S, Jackson J, et al. Alzheimer's disease in real life -- 1xbet 우회 dementia carer's survey. International Journal Geriatric Psychiatry. 2008; 23 (5): 546--551.
• *vMohamed S et al. Caregiver burden 1xbet 우회 Alzheimer disease: cross sectional and longitud1xbet 우회al patient correlates. 2010; (10):917-27. Data from Cl1xbet 우회ical antipsychotic trials of 1xbet 우회tervention effectiveness (CATIE)-AD study.
• *viAlzheimer's Association. "Alzheimer's changes 1xbet 우회 whole brain" Brain Tour. 2011. Document accessible at: http://www.alz.org/braintour/alzheimers_changes.asp.